Abstract
High-risk prostate cancer (HR Pca) is a highly heterogeneous disease from a biological and clinical standpoint, and it carries a significant chance of morbidity and mortality. Despite the impact of PSA screening, a significant number of men continue to present with high risk disease and need adequate management: clinical evidence shows that a considerable fraction on men with HR PCa can be actually cured with either uni- or multi-modality approaches. Surgical treatment, once considered unfeasible in this setting, is acquiring more and more diffusion in modern clinical practice. Herein we discuss the main treatment strategies for high-risk prostate cancer, providing an expert opinion on the role of surgical management and its outcomes in the most recent literature.
Original language | English (US) |
---|---|
Pages (from-to) | 135-143 |
Number of pages | 9 |
Journal | Critical Reviews in Oncology/Hematology |
Volume | 102 |
DOIs | |
State | Published - Jun 1 2016 |
Keywords
- High risk
- Prostate cancer
- Prostate surgery
- Radiation therapy
- Radical prostatectomy
ASJC Scopus subject areas
- Hematology
- Oncology